Scholar-in-Training Awards

The AACR is proud to offer Scholar-in-Training Awards to enable the participation of meritorious early-career scientists at the Annual Meeting 2017. Since its inception in 1986, the AACR Annual Meeting Scholar-in-Training Award program has provided more than 4,400 grants to young investigators and has received support from more than 50 cancer research foundations, corporations, individuals and other organizations dedicated to the fight against cancer. This year, fourteen organizations or individuals generously provided the funding to support this program. To commemorate the AACR’s 110th Anniversary, this funding recognizes 110 Scholar-in-Training Awardees.

The names and affiliations of the 2017 Scholar-in-Training Award recipients, along with the abstract numbers and titles of their abstracts, are listed below.

2017 AACR Scholar-in-Training Awards
AACR has graciously donated funds to support early-career investigators who will be presenting meritorious proffered papers at the AACR Annual Meeting 2017.

Mark Hafner, PhD, Harvard Medical School, Boston, MA. Abstract 972. Improving pre-clinical cancer pharmacogenomics with novel drug sensitivity metrics based on growth rate inhibition.

Matthew L. Hedberg, MD, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA. Abstract 1779. Chronic NSAID use increases survival in PIK3CA-altered head and neck squamous cell carcinoma.

Patricia M. Schneppep, BS, University of Notre Dame, Notre Dame, IN. Abstract 4934. Brain metastatic microenvironment reshapes cancer cell metabolism through epigenetic up-regulation of glutamate decarboxylase 1.

Raffaella Spina, PhD, Case Western Reserve University, Cleveland, OH. Abstract 5023. Disruption of Monocarboxylate transporter-4 Basigin interaction as an effective strategy to inhibit hypoxic response, tumor growth and vascularization, and stem cell phenotype in human glioblastoma in vitro and in vivo.

Kevin C. Vavra, PhD, Cedars-Sinai Medical Center, Los Angeles, CA. Abstract 5502. Functional evaluation of superenhancers as mediators of epithelial ovarian cancer risk.

2017 AACC-AbbVie Scholar-in-Training Awards
AbbVie has graciously donated funds to support early-career investigators who will be presenting meritorious proffered papers at the AACR Annual Meeting 2017.

Sarah E. Croessmann, PhD, Vanderbilt University, Nashville, TN. Abstract 1772. PIK3CA C2 domain deletions hyperactivate PI3K, generate oncogene dependence and are exquisitely sensitive to PI3Kα inhibitors.
Michael J. Crowley, MS, Weill Cornell Medical College, New York, NY. Abstract 4498. Targeting IRE1a-XBP1 signaling in lung cancer.

Ruben Ferrer-Luna, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 4974. Pharmacogenomic interactions in glioblastoma cell line models.

Véronique Giroux, PhD, University of Pennsylvania, Philadelphia, PA. Abstract 5022. Keratin15 (Krt15) + are radio resistant and tumor-initiating cells in the mouse small intestine.

Alissa Guarnaccia, BS, Vanderbilt University, Nashville, TN. Abstract 4994. Understanding the MYC and WDR5 interaction at chromatin.

Jason A. Hanna, PhD, St. Jude Children's Research Hospital, Memphis, TN. Abstract 461. Dichotomous roles of Dicer1 in rhabdomyosarcoma and angiosarcoma.

Isaac Spencer Harris, PhD, Harvard Medical School, Boston, MA. Abstract 4985. Understanding the vulnerabilities in cancer cells upon inhibition of glutathione synthesis.

Imran Khan, PhD, National Institute of Health (NIH), Bethesda, MD. Abstract 1047. Role of endocytosis in NM23 mediated motility suppression.

Hawley C. Pruitt, BS, University of Alabama at Birmingham, Birmingham, AL. Abstract 1046. Conditional knockout of N-Myc and STAT Interactor disrupts normal mammary development and enhances metastatic ability of mammary tumors.

Xiang Shu, PhD, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN. Abstract 1309. Association between insulin resistance and breast cancer risk: A Mendelian randomization analysis of data from 228,000 women of European descent.

Ronald F. Siebenaler, BS, University of Michigan Medical School, Ann Arbor, MI. Abstract 1362. Argonaute 2 controls RAS activation in mouse embryonic fibroblasts.

Wenting K. Tsai, BA, University of California Los Angeles, Los Angeles, CA. Abstract 1856. Dual-modality immunoPET/fluorescence imaging of prostate cancer utilizing \(^{89}\text{Zr}-\text{or }^{124}\text{I}-\text{Cy5.5-anti-PSCA cys-minibody.}\)


Juo-Chin Yao, BS, Washington University in St. Louis, St. Louis, MO. Abstract 3042. MIR142 loss-of-function mutations promote leukemogenesis through derepression of ASH1L resulting in increased HOX gene expression.
2017 AACR- American Brain Tumor Association Scholar-in-Training Awards
The American Brain Tumor Association has graciously donated funds to support young investigators who will be presenting high-quality proffered papers in brain cancer research for both primary and secondary (metastatic) brain tumors at the AACR Annual Meeting 2017.

Sebastian Brabetz, MSc. German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany. Abstract 1935. Molecular characterization of orthotopic patient-derived xenograft models of pediatric brain tumors.

Ye Chen, PhD. National University of Singapore, Singapore, Singapore. Abstract 1524. BCL6 modulates the TP53 and STAT pathways in glioma.

Jon D. Larson, PhD. St. Jude Children's Research Hospital, Memphis, TN. Abstract 3006. Oncogenic activity of H3.3 K27M in a spontaneous DIPG mouse model.

Joo Ho Lee, MD, MS. Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea. Abstract 2455. Human glioblastoma arises from the distant subventricular zone normal appearing but harboring tumor-initiating mutations.

Nalin Leelatian, MD. Vanderbilt University, Nashville, TN. Abstract 364. Mass cytometry of human glioblastoma characterizes more than 99 percent of cells and reveals intratumoral cell subsets defined by contrasting signaling network profiles.

2017 AACR-Aflac, Inc. Scholar-in-Training Awards
Support for AACR Scholar-in-Training Awards is part of Aflac's generous support of activities for early-career scientists within the AACR. These awards support early-career investigators who will be presenting meritorious proffered papers at the AACR Annual Meeting 2017.


Miriam S. Butler, PhD. Vancouver Prostate Centre, Vancouver, BC, Canada. Abstract 130. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.

Hani Choudhry, PhD. King Abdulaziz University, Jeddah, Saudi Arabia. Abstract 4512. The landscape of hypoxia-driven alternative splicing in breast cancer.


Helen L. Evans, PhD. David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA. Abstract 5221. Target engagement approaches to validate small-molecule binders of the pioneering transcription factor FOXA1.
Mohammad Fallahi-Sichani, PhD, Harvard Medical School, Boston, MA. Abstract 5561. Single-cell analysis reveals an adaptive, transiently heritable, slowly-dividing, drug-resistant state inhibitable by drug combinations.


Anton G. Henssen, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 4888. Human PGBD5 DNA transposase promotes site-specific oncogenic mutations in rhabdoid tumors.

Wan-Ying Hsieh, MS, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 1032. Identification of Ran binding protein 6 as a novel negative regulator of EGFR and candidate tumor suppressor in glioblastoma.

William Jongwook Kim, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 3035. Decomposing oncogenic transcriptional signatures to generate maps of divergent cellular states.

Ok-Seon Kwon, MS, Sogang University, Seoul, Republic of Korea. Abstract 4761. BCL2 induced by LAMTOR3-MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.

Joo Sang Lee, PhD, University of Maryland, College Park, MD. Abstract 543. Harnessing synthetic lethality to predict clinical outcomes of cancer treatment.

Na Li, PhD, Medical College of Wisconsin, Milwaukee, WI. Abstract 4685. Immune checkpoint protein VISTA is a critical regulator of the IL-23/IL-17 inflammatory axis.

David Liu, MD, Dana Farber Cancer Institute, Boston, MA. Abstract 2918. Analysis of matched pre and post cisplatin-treated muscle-invasive bladder cancer reveals a candidate cisplatin mutational signature.

Brian C. Miller, MD, PhD, Dana Farber Cancer Institute, Boston, MA. Abstract 3027. Dissecting mechanisms of anti-PD-1 therapy with massively parallel single-cell RNA-sequencing.

Thomas K. Ni, PhD, Tufts University, Boston, MA. Abstract 4995. Premature polyadenylation causes oncogenic truncations of the tumor suppressor genes BRCA1, LATS1 and MAGI3 in breast cancer.

Yashar Niknafs, BS, University of Michigan, Ann Arbor, MI. Abstract 3038. Bridging the gap between NGS data and its usability: cancer gene discovery through massive-scale transcriptomic analyses and development of a powerful web-tool for dissemination of these findings.

Shanmugam Panneer Selvam, PhD, Medical University of South Carolina, Charleston, SC. Abstract 5474. Sphingosine kinase 2/sphingosine 1-phosphate signaling regulates p16 mediated accelerated aging in normal somatic tissues and tcf21 mediated tumor suppression in lung cancer.
Jihyun Park, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 897.** PEA-15 regulates epithelial-mesenchymal transition and invasive behavior through its phosphorylation in triple-negative breast cancer.

Maoxiang Qian, PhD, St. Jude Children's Research Hospital, Memphis, TN. **Abstract 3005.** Whole-genome sequencing identified novel non-coding mutations causal of oncogene activation in T-cell acute lymphoblastic leukemia.

Jesse J. Salk, MD, PhD, University of Washington, Seattle, WA. **Abstract 3041.** Duplex Sequencing detects cancer-associated mutations arising during normal aging: Clonal evolution over a century of human lifetime.

Sambad Sharma, PhD, Wake Forest University School of Medicine, Winston-Salem, NC. **Abstract 5207.** Breast cancer-specific amplitude modulated radiofrequency electromagnetic fields (AM RF EMF) inhibits brain metastasis of breast cancer.

Paul A. Stewart, PhD, Moffitt Cancer Center, Tampa, FL. **Abstract 205.** Underlying mechanisms of genome-proteome discordance in squamous cell lung cancer.

Veronica Veschi, MD, PhD, National Institutes of Health, Bethesda, MD. **Abstract 3867.** Epigenetic siRNA and chemical screens identify SETD8 inhibition as a therapeutic strategy to reactivate p53 in high-risk neuroblastoma.

Wenwen Xu, MD, PhD, Medical College of Wisconsin, Milwaukee, WI. **Abstract 2996.** Immune checkpoint protein VISTA suppresses Toll-like receptor signaling and the production of inflammatory cytokines.

### 2017 AACR-June L. Biedler Scholar-in-Training Award

These awards are for meritorious proffered papers in the field of drug resistance to be presented at the AACR Annual Meeting 2017. These awards are made possible through the Estate of Dr. June L. Biedler and shall be used in part to increase public understanding of basic cancer research. The late Dr. Biedler was a dedicated member of AACR and a distinguished scientist at Memorial Sloan Kettering Cancer Center. Dr. Biedler believed that science communication is a cornerstone to the acceleration of progress.

Ethan Ahler, BS, University of Washington, Seattle, WA. **Abstract 5886.** High-throughput mutagenesis reveals novel mechanisms of drug resistance in the proto-oncogene Src kinase.

Luigi Formisano, MD, Vanderbilt University, Nashville, TN. **Abstract 1008.** Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer.

Carl M. Gay, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 1560.** Differential sensitivity analysis for resistant malignancies (DISARM), a novel approach for drug screen analysis, identifies common candidate drugs across platinum-resistant cancer types.
Naama Kanarek, PhD, MIT Whitehead Institute for Biomedical Research, Cambridge, MA. Abstract 4988. Genome-wide CRISPR screen and metabolite profiling reveal a new mechanism of methotrexate sensitivity.

Charissa Kim, MPhil. The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 418. Adaptive resistance to chemotherapy in triple-negative breast cancer revealed by single cell DNA and RNA sequencing.

Michael V. Ortiz, MD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 708. Prohibitin is a prognostic marker of treatment failure and therapeutic target to block chemotherapy resistance in Wilms tumor.

2017 AACR-Bristol-Myers Squibb Scholar-in-Training Awards
Bristol-Myers Squibb has graciously donated funds to support early-career investigators who will be presenting meritorious proffered papers at the AACR Annual Meeting 2017.

William S. Chen, BS, Yale School of Medicine, New Haven, CT. Abstract 977. Phenotypic analysis of single-cell breast cancer inhibition data reveals insights into EMT.

Jaqueline C. Avila, BS, The University of Texas Medical Branch, Galveston, TX. Abstract 5280. Disparity-related survival among adolescent and young adult patients with sarcomas in Texas.

Jeremy Bruce Foote, PhD, DVM, Johns Hopkins University School of Medicine, Baltimore, MD. Abstract 2993. STING signaling in breast tumor microenvironment modulates immune checkpoint blockade efficacy in the neu-N mouse model of breast cancer.

Roelof Koster, PhD, National Cancer Institute, National Institutes of Health, Bethesda, MD. Abstract 4871. Whole-exome sequencing identifies a high frequency of germline deleterious variants in cancer predisposition genes in individuals with osteosarcoma.

Ji Li, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute of MIT and Harvard, Boston, MA. Abstract 5020. A genome-scale ORF screen reveals an alternative splicing program that regulates mesenchymal and stem-like cell states in breast cancer.

Evan C. Markegard, BS, University of California, San Francisco, San Francisco, CA. Abstract 1370. EGFR-mediated Spred1 phosphorylation inhibits NF1 to sustain constitutive Ras/MAPK signaling.

Joshua L. Pan, BS, Dana-Farber Cancer Institute, Boston, MA. Abstract 5559. Using cancer dependency data to discover tumor suppressive and oncogenic functional modules.

Dharm S. Patel, BS, Rutgers University, Piscataway, NJ. Abstract 2477. Genomic instability in BRCA1-deficient cells is a result of the anti-recombinogenic activity of BLM helicase.

Brandilyn A. Peters, PhD, New York University School of Medicine, New York, NY. Abstract 4961. The oral microbiome and prospective risk for esophageal cancer: A population-based nested case-control study.
Vijay Ramani, PhD, UT Southwestern Medical Center, Dallas, TX. Abstract 1041. Binding of soluble DC-HIL to endothelial cell creates immunosuppression on premetastatic niches.

Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 375. Oncologist use and perception of large panel next generation tumor sequencing.

Shiraj Sen, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 3291. Development of a novel prognostic scoring system for patient selection in immune checkpoint inhibitor phase 1 clinical trials.

Paulina M. Wojnarowicz, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 4975. A small molecule pan Id protein antagonist shows strong antitumor activity.

Yiyi Yan, MD, PhD, Mayo Clinic, Rochester, MN. Abstract 547. Novel algorithms for spatial modeling of cellular interactions in the tumor microenvironment.

Sicong Zhang, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 4996. The m^5A hallmark of cancer: RNA demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation.

2017 AACR-Gerald B. Grindey Memorial Scholar-in-Training Award
This award is presented to a meritorious proffered paper in the field of preclinical science presented at the AACR Annual Meeting 2017. The late Dr. Grindey was a dedicated member of the AACR and a distinguished scientist at Eli Lilly and Company. The Gerald B. Grindey Memorial Fund was established in his honor and has been entrusted to the AACR to be used toward educational programs for early-career scientists engaged in preclinical cancer research.

Jessica M. Wagner, BS, Temple College of Medicine-Fox Chase Cancer Center, Philadelphia, PA. Abstract 3245. Preclinical evaluation of the imipridone family of small molecules, including analogues of clinical-stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

2017 AACR-GYRIG Scholar-in-Training Awards
Get Your Rear in Gear Philadelphia has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious proffered papers on colorectal cancer research at the AACR Annual Meeting 2017.

Rochelle E. Fletcher, BA, University of Pittsburgh Cancer Institute, Pittsburgh, PA. Abstract 1256. Non-steroidal anti-inflammatory drugs induce ER stress and have an immunomodulatory role in the suppression of colorectal tumorigenesis.

Sheetal Hardikar, MBBS, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA. Abstract 2295. Association between metformin use and the risk of colorectal adenomas: A systematic review and meta-analysis.

Billy T. Lau, PhD, Stanford University School of Medicine, Stanford, CA. Abstract 2443. Massively parallel single-cell RNA-Seq identifies diverse subpopulations displaying EMT and stem-like features.
Kevin J. Lee, PhD, University of South Alabama, Mitchell Cancer Institute, Mobile, AL. Abstract 5243. Novel non-COX inhibitory sulindac derivative with β-catenin suppressing activity reduces the formation of colorectal adenomas and adenocarcinomas in the APC+/min-FCCC mouse model.


Marla D. Lipsyc, BS, Columbia University and Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 4380. Integrative genomics analysis of metastatic colorectal cancer.

Yijun Wang, MS, PhD, University of Pittsburgh Cancer Institute, Pittsburgh, PA. Abstract 1692. KRAS-mediated therapeutic resistance abrogates immunogenic cell death in colorectal cancer cells.

Jiuli Zhou, MD, University of Nebraska Medical Center, Omaha, NE. Abstract 3458. Role of zyxin in mitosis and colon cancer.

2017 AACR Scholar-in-Training Awards in Memory of William Maness
The Estate of William Maness has graciously donated funds in his memory to the AACR to support early-career investigators who will be presenting meritorious proffered papers on melanoma research at the AACR Annual Meeting 2017.

Orsi Giricz, PhD, Albert Einstein College of Medicine, Bronx, NY. Abstract 3332. Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition.

Vancheswaran Gopalakrishnan, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 2672. Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome.

James T. Gordy, PhD, Johns Hopkins School of Public Health, Baltimore, MD. Abstract 1593. Neutralization of IL-10 enhances antitumor efficacy of dendritic cell-targeting MIP-3α-gp100 vaccine by way of type-I interferons in B16F10 mouse melanoma model.

Lei Jin, PhD, The University of Newcastle, Callaghan, Australia. Abstract 4462. ACTN4 stabilises RIPK1 to function as an oncogenic driver in melanoma.

Helen Thompson Michael, DVM, National Institutes of Health, Bethesda, MD. Abstract 1037. Progression from melanocytic nevi to melanoma is associated with increased genomic mutations in a UV-induced mouse model of human melanoma.

Marco Ranzani, PhD, Wellcome Trust Sanger Institute, Cambridge, United Kingdom. Abstract 3717. New therapies for the treatment of BRAF/NRAS wild type melanoma.

Victoria E. Wang, MD, PhD, University of California, San Francisco, San Francisco, CA. Abstract 1209. FGFR inhibition re-sensitizes BRAF/MEK dual resistant cells to the BRAF/MEK inhibitor combination.
2017 AACR-MEG Scholar-in-Training Awards
These awards are for meritorious proffered papers in molecular epidemiology that will be presented at the AACR Annual Meeting 2017, supported by the Molecular Epidemiology Working Group (MEG) of the AACR. The mission of MEG is to increase knowledge about cancer and chronic disease etiology, thereby promoting the prevention and treatment of cancer, and the improvement of public health. In addition to travel support, award recipients receive a free one-year membership to the Working Group.

Yin Cao, ScD, Massachusetts General Hospital and Harvard Medical School, Boston, MA. Abstract 3012. Long-term aspirin use and total and cancer-specific mortality.


Lang Wu, PhD, Vanderbilt University Medical Center, Nashville, TN. Abstract 1301. Identification of novel susceptibility loci and genes for prostate cancer risk: A large transcriptome-wide association study in over 143,000 subjects.

2017 AACR-Prostate Cancer Foundation Scholar-in-Training Awards
The Prostate Cancer Foundation has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious proffered papers on advanced prostate cancer at the AACR Annual Meeting 2017.

Seaho Kim, PhD, Weill Cornell Medicine, New York, NY. Abstract 1590. High intranuclear mobility of AR-v7 reveals distinct mode of transcriptional activity in prostate cancer with important therapeutic implications.

Haolong Li, MS, University of British Columbia, Vancouver, BC, Canada. Abstract 1576. UGT2B17 promotes castration-resistant prostate cancer progression through enhancing ligand-independent AR signaling.

Yingjie Xu, PhD, Boston Children's Hospital, Harvard Medical School, Boston, MA. Abstract 1231. Restoration of tumor suppression in vivo by systemic delivery of PTEN mRNA nanoparticles.
2017 AACR-Pezcoller Foundation Scholar-in-Training Awards
The Pezcoller Foundation supports these awards to enhance participation in the programs and activities of the AACR by early-career investigators residing in Europe and to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.

Salome Adam, MSc, University of Zurich, Zurich, Switzerland. Abstract 2763. Health-related quality of life among long-term prostate cancer survivors by primary treatment: A systematic review.


Giovanni Marconi, MD, University of Bologna, Bologna, Italy. Abstract 3311. The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemother.

Antonella Padella, MSc, University of Bologna, Bologna, Italy. Abstract 4671. Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients.

Clara Recasens-Zorzo, MSc, IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Abstract 2169. Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates the in vitro and in vivo activity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma.

Bangwen Xie, PhD, University of Cambridge, Cambridge, United Kingdom. Abstract 2866. Volumetric optoacoustic imaging of tumor cell death using a targeted imaging agent.

2017 AACR-SIC Scholar-in-Training Awards
The AACR-SIC Scholar-in-Training Awards are a partnership between the AACR and the Società Italiana di Cancerologia (SIC, the Italian Cancer Society). The AACR and SIC sponsor these awards to enhance participation by early-career investigators who are members of SIC, and to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.

Lorenzo Castagnoli, MSc, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Abstract 5428. Lactate production as a potential marker of HER2-addiction and Trastuzumab susceptibility.

Alessandra Cataldo, PhD, IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Abstract 5437. miR-302b as adjuvant therapeutic tool to improve chemotherapy efficacy in human triple-negative breast cancer.

Rosaria Chilà, MSc, IRCCS - Institute for Pharmacological Research Mario Negri, Milan, Italy. Abstract 2352. Effect of inhibition of cell cycle versus transcription cyclin-dependent kinases (CDKs) in ovarian cancer cells.
Federica Guffanti, MSc, IRCCS - Institute for Pharmacological Research Mario Negri, Milan, Italy. Abstract 508. DNA repair status in a patient derived ovarian cancer xenobank.

Andrea Resovi, PhD, IRCCS - Institute for Pharmacological Research Mario Negri, Milan, Italy. Abstract 2981. Identification of circulating stroma-related biomarkers for pancreatic ductal adenocarcinoma.

Michele Sommariva, PhD, University of Milan, Milan, Italy. Abstract 3699. Activation of NK cells cytotoxicity mediated by alveolar macrophages in the lung against murine melanoma metastases by combined aerosol immunotherapy.

Piera Tocci, PhD, Regina Elena National Cancer Institute, Rome, Italy. Abstract 1197. Endothelin-1 receptor/β-arrestin1 is an actionable node that regulates YAP/TAZ signaling and chemoresistance in high-grade ovarian cancer.

Ignazia Tusa, PhD, University of Florence, Firenze, Italy. Abstract 3904. Inhibition of the ERK5 pathway as a novel approach to target human chronic myeloid leukemia stem cells.

2017 AACR-Warner Fund Scholar-in-Training Awards
The Warner Fund has graciously donated funds to the AACR to support early-career investigators who will be presenting a proffered paper relating to cholangiocarcinoma.

Majda Haznadar, PhD, National Cancer Institute, Bethesda, MD. Abstract 2500. Urinary metabolites are diagnostic biomarkers of liver cancer.

Jessica L. Petrick, PhD, National Cancer Institute, Bethesda, MD. Abstract 3007. Tobacco smoking, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project.